The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis (CONCLUDE)
A Randomised Double-Blind Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Cobitolimod as an Induction and Maintenance Therapy in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis
Sponsor: InDex Pharmaceuticals
Terminated
Due to futility
Other Ulcerative Colitis trials with similar outcome
A PHASE3 clinical study on Ulcerative Colitis, this trial is terminated or withdrawn. The trial is conducted by InDex Pharmaceuticals and has accumulated 9 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2024 — Jul 2024 [monthly]
Terminated PHASE3
Status: Recruiting → Terminated
-
Jan 2023 — Jan 2024 [monthly]
Recruiting PHASE3
▶ Show 4 earlier versions
-
Sep 2022 — Jan 2023 [monthly]
Recruiting PHASE3
-
Feb 2022 — Sep 2022 [monthly]
Recruiting PHASE3
-
Dec 2021 — Feb 2022 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Sep 2021 — Dec 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- InDex Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aalborg, Denmark , Aarhus, Denmark , Amadora, Portugal , Ankara, Turkey (Türkiye) , Antwerp, Belgium , Ashkelon, Israel , Augsburg, Germany , Banja Luka, Bosnia and Herzegovina , Banská Bystrica, Slovakia , Batumi, Georgia and 164 more locations